Clinical trial
I-125 Versus Pd-103 for Medium Risk Prostate Cancer
NCT00486499 · VA Puget Sound Health Care System, U.S. Fed · Unknown status
Key facts
| NCT number | NCT00486499 |
|---|---|
| Title | I-125 Versus Pd-103 for Medium Risk Prostate Cancer |
| Lead sponsor | VA Puget Sound Health Care System, U.S. Fed |
| Collaborators | Dr. Gregory Merrick Theragenics Corporation Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Procedure |
| Interventions | I-125 versus Pd-103 radioactive seed insertion |
| Enrollment | 660 |
| Start date | Mar 1, 2003 |
| First posted | Jun 14, 2007 |
| Last update posted | Jun 14, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: